GLP3-R (Retatrutide)
A high-purity triple-agonist peptide synthesized for metabolic and weight regulation research. Supplied in lyophilized form for maximum stability.
GLP3-R Overview
Retatrutide (GLP3-R) is a synthetic triple-agonist peptide that simultaneously targets three key metabolic hormone receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). This multi-receptor mechanism distinguishes it from earlier single and dual agonists, positioning it at the forefront of metabolic and weight regulation research.
Supplied as a lyophilized powder, each batch is handled under strict quality control standards to ensure identity, purity, and consistency across research applications.
Jastreboff AM et al. (2023)History
Retatrutide was first described in peer-reviewed literature in 2022 following preclinical work by Eli Lilly researchers studying multi-receptor agonism as a strategy for metabolic disease. Early investigations focused on its combined GIP, GLP-1, and glucagon receptor activity, establishing the foundation for its use as a research tool in obesity and metabolic syndrome studies.
Phase 2 trial results published in 2023 in the New England Journal of Medicine demonstrated weight loss outcomes that exceeded those of all prior single and dual agonist compounds, generating significant interest in the research community.
Coskun T. et al. (2022)Research Findings
Retatrutide has been studied extensively in metabolic, weight regulation, and endocrine models. Research focuses on its triple-receptor mechanism and its ability to produce compound metabolic effects beyond what single or dual agonists achieve. Studies highlight its role in appetite regulation, fat mass reduction, glycemic control, and energy metabolism.
- Metabolic: Weight regulation, fat mass, energy balance
- Endocrine: GLP-1, GIP, and glucagon receptor signaling
- Glycemic: Insulin sensitivity, glucose-dependent mechanisms
- Systemic: Appetite suppression, body composition dynamics
Collectively, these findings establish Retatrutide as one of the most significant research tools in metabolic science, offering a multi-pathway platform for studying energy homeostasis, fat regulation, and receptor agonism in preclinical settings.
Jastreboff AM et al. 2023References
Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 389:514–526.
Coskun T, et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. 35(6):1–14.
Urva S, et al. (2024). Pharmacokinetics and pharmacodynamics of retatrutide, a GIP, GLP-1 and glucagon receptor agonist in type 2 diabetes. Diabetes, Obesity and Metabolism.
Our Process
Precision Synthesis
Manufactured to strict purity standards at advanced synthesis facilities.
Verified Purity
Every batch handled under strict quality control for identity and consistency.
Same-Day Fulfillment
Cold-stored and shipped same day from our fulfillment facility.
⚠️ RESEARCH USE ONLY
All products are provided exclusively for research, laboratory, or analytical use and are strictly not for human consumption. The statements on this page have not been evaluated by the U.S. Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any medical condition or disease. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.
Reviews
There are no reviews yet.